Literature DB >> 9159720

Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease.

J G Nutt1, J H Carter, E S Lea, W R Woodward.   

Abstract

The cause of motor fluctuations occurring during constant-rate levodopa infusions is unknown. We examined whether known pharmacokinetic factors could explain the fluctuations and looked for clues to pharmacodynamic causes. Eleven subjects with stage III-V Parkinson's disease (PD) and a fluctuating response to levodopa underwent constant-rate infusions for 36-110 h. Levodopa, 3-O-methyldopa (3-OMD), and plasma large neutral amino acids (LNAAs) were measured at 2- to 6-h intervals and PD was monitored hourly from 07:00 to 22:00 h with tapping speed. Ten subjects had motor fluctuations during the infusions. Zero to 68% of the variability of tapping speed could be explained by variation in plasma LNAA concentrations in individual subjects. Fluctuations occurred more commonly later in the day, which may be related to the tendency for LNAAs to increase during the day. Motor fluctuations were not associated with minor variations in levodopa or 3-OMD concentrations. Fluctuations during constant infusions were more marked in patients using larger daily doses of oral levodopa; severity of PD did not predict fluctuations during the infusions. There was no trend for fluctuations or dyskinesia to decrease or increase during several days of constant-rate levodopa infusion. A portion of motor fluctuations occurring during constant levodopa infusions can be explained by peripheral pharmacokinetic mechanisms. Fluctuations are more prominent in subjects who have taken larger daily doses of levodopa, implicating pharmacodynamic factors as well.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9159720     DOI: 10.1002/mds.870120304

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  18 in total

Review 1.  Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management.

Authors:  Teus van Laar
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 2.  Continuous drug delivery in early- and late-stage Parkinson's disease as a strategy for avoiding dyskinesia induction and expression.

Authors:  P Jenner; A C McCreary; D K A Scheller
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

3.  Psychometric Properties of Activity, Self-Efficacy, and Quality-of-Life Measures in Individuals with Parkinson Disease.

Authors:  Vanina Dal Bello-Haas; Laura Klassen; M Suzanne Sheppard; Amy Metcalfe
Journal:  Physiother Can       Date:  2011-01-20       Impact factor: 1.037

Review 4.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

Review 5.  A New Perspective for Parkinson's Disease: Circadian Rhythm.

Authors:  Siyue Li; Yali Wang; Fen Wang; Li-Fang Hu; Chun-Feng Liu
Journal:  Neurosci Bull       Date:  2016-12-19       Impact factor: 5.203

Review 6.  Available and emerging treatments for Parkinson's disease: a review.

Authors:  Patrick Hickey; Mark Stacy
Journal:  Drug Des Devel Ther       Date:  2011-05-02       Impact factor: 4.162

Review 7.  Closing the loop for patients with Parkinson disease: where are we?

Authors:  Hazhir Teymourian; Farshad Tehrani; Katherine Longardner; Kuldeep Mahato; Tatiana Podhajny; Jong-Min Moon; Yugender Goud Kotagiri; Juliane R Sempionatto; Irene Litvan; Joseph Wang
Journal:  Nat Rev Neurol       Date:  2022-06-09       Impact factor: 44.711

8.  Dissociable effects of dopamine on learning and performance within sensorimotor striatum.

Authors:  Daniel K Leventhal; Colin Stoetzner; Rohit Abraham; Jeff Pettibone; Kayla DeMarco; Joshua D Berke
Journal:  Basal Ganglia       Date:  2014-06-01

9.  Continuous levodopa for advanced Parkinson's disease.

Authors:  Christofer Lundqvist
Journal:  Neuropsychiatr Dis Treat       Date:  2007-06       Impact factor: 2.570

Review 10.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.